Related Content
- FDA approves Merck's Gardasil for prevention of anal cancer
- Medco study: Half of women 40 years and older don’t get annual mammograms
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Medication adherence could be blockbuster for specialty
INDIANAPOLIS — Cancer patients taking a drug made by Eli Lilly extended the amount of time they survived without their disease worsening, according to results of a study announced Sunday.
Lilly said results of the phase-3 “PARAMOUNT” study of the injected drug Alimta (pemetrexed) extended progression-free survival in patients with nonsquamous nonsmall-cell lung cancer. The study focused on continuation maintenance when one of the same drugs used as a first-line treatment for cancer is continued as maintenance therapy in an effort to control the disease.
Results were presented Sunday at the 47th annual meeting of the American Society of Clinical Oncology in Chicago.
